EXPLEOSOL
Expleo Solutions Limited
Each stock's 10,000-path forecast, rendered as light.
Expleo Solutions Limited (EXPLEOSOL) Stock Analysis & Case Study
Is EXPLEOSOL a good buy? The data-driven verdict.
Expleo Solutions Limited (EXPLEOSOL) trades at ₹837,on the numbers it screens attractive, a Downstox Snapshot Score of 80/100.
On the numbers, Expleo Solutions Limited (EXPLEOSOL) screens attractive, a Downstox Snapshot Score of 80/100, weighing inexpensive at 9.8× earnings, ROE of 18.7%, a 51% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
EXPLEOSOL fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How EXPLEOSOL ranks against the 2,373 companies in our screener
- EXPLEOSOL's market cap of 1,299 Cr ranks in the 43rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EXPLEOSOL's book value of ₹500 ranks in the 90th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EXPLEOSOL's promoter holding of 71.0% ranks in the 77th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EXPLEOSOL's 3-year revenue growth of 7.0% ranks in the 41st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EXPLEOSOL's debt-to-equity ratio of 0.01x is lower than 98% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
We do not hold a 3-year profit (PAT) growth figure for EXPLEOSOL, as of 9 Aug 2026, so it is not ranked here.
Is EXPLEOSOL overvalued? EXPLEOSOL P/E vs peers
EXPLEOSOL trades at 9.8× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
EXPLEOSOL share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of EXPLEOSOL history (4%/yr drift, 39%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| EXPLEOSOL 2027 | ₹518 | ₹848 | ₹1,387 | +1% |
| EXPLEOSOL 2028 | ₹427 | ₹858 | ₹1,725 | +3% |
| EXPLEOSOL 2029 | ₹365 | ₹869 | ₹2,071 | +4% |
| EXPLEOSOL 2030 | ₹323 | ₹881 | ₹2,405 | +5% |
| EXPLEOSOL 2031 | ₹295 | ₹892 | ₹2,700 | +7% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability EXPLEOSOL goes up, or doubles?
The bull case for EXPLEOSOL
- EXPLEOSOL's P/E of 9.8x is lower than 86% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EXPLEOSOL's return on equity of 18.7% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EXPLEOSOL's return on capital employed of 24.2% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- EXPLEOSOL's dividend yield of 13.2% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,071.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹365.
EXPLEOSOL volatility & expected range, how bumpy is the ride?
Over the last 9.8 years EXPLEOSOL compounded at 4%/year with annualized volatility of 39%. That volatility implies a 1-year 80% range of ₹518-₹1,387, the honest backbone behind any single price target.
EXPLEOSOL price forecast, the full 60-month probability fan
EXPLEOSOL price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds EXPLEOSOL hits common targets within the simulated horizon?
Full multi-horizon detail on the EXPLEOSOL price target & forecast page.
EXPLEOSOL Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. EXPLEOSOL scores 5/8, mixed financial health.
EXPLEOSOL MTF margin & leverage across 8 brokers
Margin Trading Facility lets you buy EXPLEOSOL with part of the capital. Lower margin % = higher leverage. Rates compared across 8 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 33.17% | 3.0× |
| Groww | 33.33% | 3.0× |
| Dhan | 40.00% | 2.5× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 43.22% | 2.3× |
| Pocketful | 50.00% | 2.0× |
| Anand RathiCHEAPEST | 33.17% | 3.0× |
| Share India | 33.29% | 3.0× |
Compare every broker on the EXPLEOSOL MTF page.
About Expleo Solutions Limited: sector, index & market-cap context
Expleo Solutions Limited (EXPLEOSOL) is a small-cap NSE-listed company, with a market capitalisation of ₹1,299 Cr. See more stocks on our screener.
How the EXPLEOSOL Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Expleo Solutions Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
EXPLEOSOL analysis, FAQs
Is Expleo Solutions Limited (EXPLEOSOL) a good buy?
On the numbers, Expleo Solutions Limited (EXPLEOSOL) screens attractive, a Downstox Snapshot Score of 80/100, weighing inexpensive at 9.8× earnings, ROE of 18.7%, a 51% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is EXPLEOSOL overvalued or undervalued?
EXPLEOSOL trades at 9.8× earnings, inexpensive versus the ~22× long-run Nifty average.
What is the EXPLEOSOL share price target for 2031?
EXPLEOSOL's probability-weighted 2031 median target is ₹892, with an 80% range of ₹295-₹2,700 (10,000-path Monte-Carlo).
What is the probability EXPLEOSOL doubles in 5 years?
The modelled probability of EXPLEOSOL reaching ₹1,674 (2×) within 5 years is 24%.
What is the bull case for EXPLEOSOL?
EXPLEOSOL's P/E of 9.8x is lower than 86% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. EXPLEOSOL's return on equity of 18.7% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. EXPLEOSOL's return on capital employed of 24.2% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in EXPLEOSOL?
No model or past record guarantees future returns, treat this as one input, not a decision.